Latest ebit for NMRD: $-9.9M, below the Healthcare sector average of $23B.
Get informed when a big investor buys or sells
+ FollowAs of Dec 31, 2023
Trailing 12 months ending Dec 31, 2023
Nemaura Medical's ebit stands at $-9.9M as of December 2023. That compares with $-7.9M in the prior-year period — down 26.4% year over year. That is below the Healthcare sector average of $23B. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Nemaura Medical reported $-9.9M in EBIT versus $-7.9M a year earlier — a 26.4% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.
Nemaura Medical sits lower the Healthcare benchmark ($23B) with a EBIT of $-9.9M. That is roughly 100.0% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
That compares with $-7.9M in the prior-year period — down 26.4% year over year. Sustained growth in EBIT can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.
The history chart shows how Nemaura Medical's EBIT evolved across reporting periods, while the comparison chart places NMRD next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.